In addition, the special genomic, proteomic, and metabolomic features of pancreatic cancer patients should also continue to be studied in depth, with a multi-omics macro-cut into the role of STAT3 in pancreatic cancer, leading to the design of more effective STAT3 inhibitors. Here, STAT3 is linked to familial pancreatic carcinoma.